Researchers claim that pharmaceutical company GlaxoSmithkline has tried to influence the debate on the safety of diabetes treatment drug Avandia, also known as rosiglitazone, which the company manufactures.
A new study claims that more than nine out of ten scientists who backed the drug had financial links to the pharmaceutical industry.
Researchers from the Mayo Clinic in Minnesota analysed more than 200 articles published in scientific journals, including original papers, editorials and letters, which commented on the heart attack risk associated with Avandia after 2007.
“The Medicines and Healthcare products Regulatory Agency (MHRA), who are responsible for the licensing of drugs in the UK, currently state that glitazones are a safe and effective treatment for Type 2 diabetes," said Cathy Moulton, Care Advisor at Diabetes UK.
"In the UK, Glitazones are not presently recommended for people who have had, or who are at high risk of having, heart failure."
“We would advise people with diabetes who use Avandia not to stop taking their medication but If they are worried they should speak to their healthcare team as soon as possible.”